A man in his sixties on thrice-weekly haemodialysis mentions, almost in passing, that a relative has brought him a jar of haritaki powder from India. He has heard it cleanses the body and might help him focus during the long hours on the machine. He wants to know if he can take a spoonful each morning. Most nephrology teams will meet some version of this conversation, and many will meet it without having been taught what to say.
Ayurvedic herbs are no longer a niche interest. People living with chronic kidney disease (CKD) are a group with strong reasons to look for something beyond standard care: the illness is long, the treatment is demanding, and symptoms such as fatigue, itch and restless legs often respond only partially to medication. This article sets out what clinicians and students should know when these questions come up.
Haritaki is the dried fruit of Terminalia chebula. Revered in classical Ayurvedic texts, it is mostly taken as a powder or tablet for constipation and bowel regularity. Triphala is a combination of three fruits: haritaki, bibhitaki (Terminalia bellirica) and amalaki (Phyllanthus emblica, Indian gooseberry). It is one of the most widely sold Ayurvedic formulations.
Both are rich in tannins and polyphenols, including chebulic and chebulinic acids, gallic acid and ellagic acid. Their best-recognised pharmacological effect in humans is laxative. That one fact matters more for a patient with advanced CKD than most of the claims printed on the packaging.
There is a sizeable preclinical literature on Terminalia chebula. Cell and animal studies describe antioxidant, anti-inflammatory and, in some rodent models, protective effects against drug-induced or diabetic kidney injury. They are not evidence that haritaki slows CKD progression in people, improves eGFR, or is safe in patients with reduced renal clearance.
Human data are thin. Small triphala trials have mostly studied constipation, dental plaque or metabolic markers in people without kidney disease. There are no robust clinical trials showing benefit for patients with CKD, and none that establish safe dosing in stage 4 or 5 disease or on dialysis. When a patient asks whether it will help their kidneys, the honest answer is that it has not been shown to.
A remedy that is reasonably well tolerated by a healthy adult can behave differently in someone whose kidneys no longer regulate fluid and electrolytes. Several concerns deserve attention.
Fluid and electrolyte shifts. A laxative herb that causes loose stools can lead to volume depletion, low blood pressure and electrolyte disturbance. In a dialysis patient with carefully balanced fluid status, or one whose residual function the team is trying to preserve, dehydration is not trivial.
Potassium. Plant-based powders and decoctions can contribute potassium, and the content is rarely stated on the label. Diarrhoea can also move potassium unpredictably. For patients on a potassium-restricted diet, any unlabelled botanical product is an unknown quantity.
Contaminants. Published analyses of some Ayurvedic products sold internationally have found lead, mercury or arsenic, sometimes deliberately included in traditional metal-based preparations (rasa shastra) and sometimes as contamination. Heavy metals are nephrotoxic, and patients with CKD clear them poorly.
Interactions. High-tannin preparations can, in principle, reduce absorption of some oral drugs and iron if taken at the same time. Formal interaction data for haritaki are limited, which is itself a reason for caution in patients on phosphate binders, antihypertensives, immunosuppressants after transplant or anticoagulants.
Blood pressure. Volume loss from laxative use can drop blood pressure in patients already on several antihypertensives, and intradialytic hypotension is a familiar problem without adding to it.
The history of herbal nephrotoxicity offers a sober reminder. Aristolochic acid nephropathy showed how a substituted herb in a product believed to be harmless can cause irreversible kidney damage. Haritaki is not implicated, but the episode illustrates why product identity, sourcing and quality matter as much as the named ingredient.
It can help to know that caution is not only a biomedical position. Many qualified Ayurvedic practitioners themselves advise against strong purgative herbs in frail, elderly or severely ill patients. A publicly posted consultation on whether haritaki is safe in kidney disease is a good example: a person with stage 5 CKD on dialysis, with hypertension, raised uric acid and restless legs, asked about taking the herb to support meditation, and the Ayurvedic doctor who replied advised avoiding it entirely, citing its laxative and dehydrating effect, electrolyte concerns and the risk of a sudden fall in blood pressure. The reply suggested breathing practices and meditation during dialysis instead.
Patients rarely volunteer herbal use unless asked, and a generic question about "any other medicines" tends to miss it. Many people do not think of a powder from a relative or a tea from a health shop as medicine. Questions that tend to work better are specific and non-judgemental.
Do you take any herbal powders, teas, tablets or oils, including ones from home or family?
Has anyone recommended something for your kidneys, your energy, your sleep or your bowels?
Where did you get it, and do you still have the packet or a photo of the label?
How much do you take, how often, and for how long?
Have you noticed any change in your bowels, thirst, dizziness or cramps since starting it?
Asking to see the product is useful. The label may reveal a multi-ingredient formulation, a metal-based preparation or a manufacturer with no traceable quality standards. Recording the product name helps if unexplained abnormalities, such as a rise in potassium, appear later.
The goal is safety, but the conversation goes better when the patient feels heard. A patient who is told bluntly that herbs are nonsense may simply stop mentioning them. Some practical approaches:
Acknowledge the reason behind the question. Most patients want relief from a specific symptom. Address it directly.
Be clear about advanced disease. In stage 4 to 5 CKD, on dialysis or after transplant, it is reasonable to advise avoiding haritaki, triphala and other laxative or multi-herb products unless the renal team has reviewed them.
Offer alternatives. Constipation in dialysis patients can be managed with options the team understands and can monitor. Restless legs warrant checking iron status, dialysis adequacy and medication review.
Respect non-drug practices. Meditation, slow breathing and gentle movement carry little renal risk and can be encouraged.
Agree a plan if the patient continues. If someone is determined to keep taking a product, ask them to tell the team, bring the packaging, and accept closer monitoring of electrolytes and blood pressure.
Many patients search for answers before they ask their care team. Appointments feel short and online platforms reply quickly. Some of those replies are careful, as in the consultation above. Others promise detoxification or kidney regeneration with no basis. Clinicians cannot control what patients read, but they can make it easy to bring those questions into the clinic. A simple line at the end of a consultation, "If you read about any herb or supplement, ask us before you start it," signals that the topic is welcome.
For medical students and junior doctors, the lesson is broader than one herb. Integrative questions are part of routine care for people with chronic illness. Knowing the commonest products, the vulnerabilities of reduced kidney function and the right history questions will prevent more harm than any blanket rule. The man with the jar of haritaki is not being unreasonable. He is trying to feel better, and he deserves an answer that is both honest and kind.
MBTpg/MSM
